about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Af­ter blue­print­ing R&D hub, Ab­b­Vie dish­es out $105M for CD39 pact with Tizon­a's new CEO from Roche

7 years ago
R&D
Pharma

With ear­ly-stage stud­ies un­der­way, Con­nect Bio­phar­ma­ceu­ti­cals clos­es $55M round to ad­vance im­mune mod­u­la­tors

7 years ago
Financing
Startups

Boyu Cap­i­tal helps point Cel­gene-part­nered An­ten­gene down a quick path to com­mer­cial­iza­tion

7 years ago
Financing

Chi­na green­lights sec­ond home­grown PD-1 in 10 days as In­novent cel­e­brates its first drug OK with Eli Lil­ly

7 years ago
China
Pharma

Can No­var­tis slim down CAR-T man­u­fac­tur­ing time­lines with its lat­est ac­qui­si­tion at­tempt?

7 years ago
Deals

Col­in Fre­und takes new CEO job at Mod­ra Phar­ma; Com­pass re­cruits Pfiz­er, Bio­gen vets to C-suite

7 years ago
Peer Review

Boehringer of­floads an mTOR can­cer drug as Xy­nom­ic plots a quick ad­vance in the clin­ic

7 years ago
R&D
Pharma

On the heels of Chi­na ap­proval, Fi­bro­Gen and As­traZeneca spot­light more pos­i­tive PhI­II da­ta for rox­adu­s­tat

7 years ago
R&D

Biotech bound, Liz Bar­rett pass­es No­var­tis' top on­col­o­gy job to Su­sanne Schaf­fert

7 years ago
People

River­Vest ready to roll with Fund IV af­ter clos­ing the till with $184M

7 years ago
Financing

Ready to con­sum­mate its Shire buy­out, Take­da plans US dual list­ing while NYSE los­es a ma­jor phar­ma to Nas­daq

7 years ago
Pharma

No­vo helps birth start­up ad­vanc­ing an As­traZeneca castoff with $15M; Japan's Fu­ji Phar­ma wa­gers $50M on Alvotech's ...

7 years ago
News Briefing

Jun­shi wins the race for first made-in-Chi­na PD-1 ap­proval as ex­ecs reap $394M IPO har­vest

7 years ago
Financing
China

Broad­en­ing its on­col­o­gy fo­cus, In­novent adds three In­cyte drugs to port­fo­lio for $40M cash

7 years ago
R&D
China

Soft­ware de­vel­op­er Syn­thace rais­es $25.6M to re­al­ize 'com­put­er aid­ed bi­ol­o­gy'

7 years ago
Financing
AI

Shinichi Tamu­ra re­claims the throne at So­sei; Jeff Abbey ex­its Ar­gos for No­vadip; Frank Cz­er­wiec is the new CMO at ...

7 years ago
Peer Review

Two years and $78M lat­er, Am­gen wash­es its hands of Ad­vax­is' I/O drug — and shares plum­met

7 years ago
Pharma

Flag­ship-backed Foghorn woos Bris­tol-My­ers vet Carl De­ci­c­co to di­rect its 'gene traf­fic con­trol' plat­form

7 years ago
People

WuXi AppTec cruis­es to­ward a steady de­but in Hong Kong stock ex­change, end­ing flat on IPO price

7 years ago
Financing
China

Up­start Akero con­tin­ues its swoosh in­to NASH space with $70M wind­fall round

7 years ago
Financing

Clive Mean­well gives way to new CEO as ac­tivist in­vestor Alex Den­ner shakes up The Med­i­cines Com­pa­ny

7 years ago
People

Sue Dil­lon, Karyn O'Neil steer fledg­ling Aro Bio­ther­a­peu­tics to $13M de­but — with J&J's bless­ing

7 years ago
Financing
Startups

WuXi AppTec starts a glob­al wave of ex­pan­sion, jump­ing off in San Diego fol­low­ing $1B Hong Kong IPO raise

7 years ago
Financing

Gilead locks in Daniel O'­Day as CEO, tap­ping the Roche vet to re­ju­ve­nate growth

7 years ago
People
First page Previous page 106107108109110111112 Next page Last page
A service from the Financial Times